| scholarly article | Q13442814 |
| P2093 | author name string | Wang Y | |
| Ritz J | |||
| Anderson KC | |||
| Neuberg D | |||
| Canning C | |||
| Soiffer RJ | |||
| Alyea EP | |||
| Schlossman R | |||
| Collins H | |||
| Pickett C | |||
| P433 | issue | 10 | |
| P304 | page(s) | 3671-3680 | |
| P577 | publication date | 1998-05-01 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant | |
| P478 | volume | 91 |
| Q36062047 | A long road of T-cells to cure cancer: from adoptive immunotherapy with unspecific cellular products to donor lymphocyte infusions and transfer of engineered tumor-specific T-cells. |
| Q24531314 | ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction |
| Q24539030 | Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission |
| Q40673497 | Antigens shared by malignant plasma cells and normal B cells may be involved in graft versus myeloma |
| Q35848136 | Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia |
| Q30859024 | CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. |
| Q30679410 | CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia |
| Q38219579 | Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches |
| Q36612643 | Cellular therapy following allogeneic stem-cell transplantation |
| Q37183578 | Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation |
| Q37420778 | Dendritic cell-based immunotherapy for myeloid leukemias. |
| Q24604091 | Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia |
| Q36819337 | Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies |
| Q35651730 | Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model |
| Q39753388 | Divide and conquer: Blocking graft versus host but not graft versus leukemia T cells with agonist BTLA co-inhibitory signals |
| Q30558271 | Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose |
| Q34755262 | Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans |
| Q33526746 | Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells |
| Q38742867 | Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: past, present and future. |
| Q43196417 | Ex vivo expanded cord blood CD4 T lymphocytes exhibit a distinct expression profile of cytokine-related genes from those of peripheral blood origin. |
| Q35828638 | Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse. |
| Q36825001 | Graft-versus-host disease after donor leukocyte infusions: presentation and management |
| Q24670205 | Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor |
| Q36816176 | Granulocyte colony-stimulating factor-primed bone marrow: an excellent stem-cell source for transplantation in acute myelocytic leukemia and chronic myelocytic leukemia |
| Q33566388 | HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation |
| Q35199782 | Harvesting, processing and inventory management of peripheral blood stem cells |
| Q35849099 | Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions |
| Q38580545 | Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies |
| Q88152658 | Infusion of donor-derived CD8+ memory T cells for relapse following allogeneic hematopoietic cell transplantation |
| Q34378623 | Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. |
| Q34202277 | NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantatio |
| Q26770391 | Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic) |
| Q35877000 | Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation |
| Q37817036 | Prevention of GVHD without losing GVL effect: windows of opportunity |
| Q87495925 | Quantitative chimerism: an independent acute leukemia prognosis indicator following allogeneic hematopoietic SCT |
| Q38789518 | Recent advances in T-cell immunotherapy for haematological malignancies |
| Q34678309 | Relapsed multiple myeloma |
| Q37609441 | Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion |
| Q35060002 | Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation |
| Q37148120 | Risk-adapted donor lymphocyte infusion based on chimerism and donor source in pediatric leukemia. |
| Q33779931 | Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens. |
| Q37375614 | Tumor protective activity of CD4+ but not of CD8+ T cells in DNA-vaccinated mice challenged with bcr-abl-transformed cells |
Search more.